Abstract
The options for frontline chronic lymphocytic leukemia (CLL) treatment continue to expand. Therapies include monotherapy with a Bruton's tyrosine kinase inhibitor (BTKi), doublet therapies such as venetoclax with intravenous obinutuzmab or an oral BTKi, and triplet therapy combining BTKi, venetoclax, and CD20 antibody. Treatment duration also is increasingly variable, from fixed duration to utilization of undetectable minimal residual disease (uMRD) to determine optimal treatment completion. Currently, the best option for an individual patient requires a multifaceted approach considering the individual's cytogenetics, comorbidities, and personal preferences, including time-limited therapy vs continuous treatment. In this article, we outline the current state of frontline CLL including ongoing questions and future directions.
References
1.
Hallek
M
, Cheson
BD
, Catovsky
D
, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
. Blood
. 2018
;131
(25
):2745
-2760
.2.
Alrawashdh
N
, Sweasy
J
, Erstad
B
et al. Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985–2017)
. Ann Hematol
2021
;100
(10
):2501
-2512
.3.
NCCN
. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Version 3.2025)
. 2025
.4.
Thompson
PA
, Bazinet
A
, Wierda
WG
, et al. Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up
. Blood
. 2023
; 142
(21
):1784
-1788
.5.
Al-Sawaf
O
, Zhang
C
, Jin
HY
, et al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
. Nat Commun
. 2023
;14
(1
):2147
.6.
Tausch
E
, Schneider
C
, Robrecht
S
, et al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax
. Blood
. 2020
;135
(26
):2402
-2412
.7.
Stilgenbauer
S
, Sander
S
, Bullinger
L
, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival
. Haematologica
. 2007
;92
(9
):1242
-1245
.8.
Sharman
JP
, Egyed
M
, Jurczak
W
, et al. Efficacy and safety in a 4-year follow- up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
. Leukemia
. 2022
;36
(4
):1171
-1175
.9.
Le Bris
Y
, Struski
S
, Guièze
R
, et al. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia
. Hematol Oncol
. 2017
;35
(4
):664
-670
.10.
Brown
JR
, Eichhorst
B
, Hillmen
P
, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia
. N Engl J Med
. 2023
;388
(4
):319
-332
.11.
Byrd
JC
, Hillmen
P
, Ghia
P
, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial
. J Clin Oncol
. 2021
;39
(31
):3441
-3452
.12.
Barr
PM
, Owen
C
, Robak
T
, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
. Blood Adv
. 2022
;6
(11
):3440
-3450
.13.
Tam
CS
, Brown
JR
, Kahl
BS
, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
. Lancet Oncol
. 2022
;23
(8
):1031
-1043
.14.
Shadman
M
, Munir
T
, Robak
T
, et al. Zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA
. J Clin Oncol
. 2025
;43
(7
):780
-787
.15.
Tam
CSL
, Ghia
P
, Shadman
M
et al. SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
. J Clin Oncol
. 2025
; 43
(Suppl 16
):7011
.16.
Sharman
JP
, Egyed
M
, Jurczak
W
, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial
. Lancet
. 2020
;395
(10232
):1278
-1291
.17.
Sharman
JP
, Egyed
M
, Jurczak
W
, et al. Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN
. Blood
. 2025
;146
(11
):1276
-1285
.18.
Al-Sawaf
O
, Zhang
C
, Lu
T
, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study
. J Clin Oncol
. 2021
;39
(36
):4049
-4060
.19.
Fürstenau
M
, Kater
AP
, Robrecht
S
, et al. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
. Lancet Oncol
. 2024
;25
(6
):744
-759
.20.
Fürstenau
M
, Robrecht
S
, von Tresckow
J
, et al. The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs progression-free survival compared to venetoclax-CD20-antibody combinations and chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia: final analysis from the phase 3 GAIA/CLL13 trial. EHA2025 Congress
; 2025
:S191
.21.
Deng
J
, Isik
E
, Fernandes
SM
, Brown
JR
, Letai
A
, Davids
MS
. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
. Leukemia
. 2017
; 31
(10
):2075
-2084
.22.
Kater
AP
, Owen
C
, Moreno
C
, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities
. NEJM Evid.
2022
;1
(7
):EVIDoa2200006.23.
Munir
T
, Moreno
C
, Owen
C
, et al. Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib- venetoclax versus chlorambucil-obinutuzumab in the GLOW study
. J Clin Oncol
. 2023
;41
(21
):3689
-3699
.24.
Tam
CS
, Allan
JN
, Siddiqi
T
, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
. Blood
. 2022
;139
(22
):3278
-3289
.25.
Niemann
CU
, Munir
T
, Owen
C
et al. First-line ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab in elderly or comorbid patients (pts) with chronic lymphocytic leukemia (CLL): Glow study 64-month follow-up (FU) and adverse event (AE)-free progression-free survival (PFS) analysis
. Blood
2024
; 144
(Suppl 1
):1871
.26.
Eichhorst
B
, Niemann
CU
, Kater
AP
, et al; GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland
. First-line venetoclax combinations in chronic lymphocytic leukemia
. N Engl J Med
. 2023
;388
(19
):1739
-1754
.27.
Brown
JR
, Seymour
JF
, Jurczak
W
, et al; AMPLIFY investigators fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia
. N Engl J Med.
2025
;392
(8
):748
-762
.28.
Wierda
WG
, Jacobs
R
, Barr
PM
et al. Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): up to 5.5 years of follow-up in the phase 2 CAPTIVATE study
. J Clin Oncol
. 2024
;42
(Suppl 16
):7009
.29.
Munir
T
, Cairns
DA
, Bloor
A
, et al; National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup
. Chronic lymphocytic leukemia therapy guided by measurable residual disease
. N Engl J Med
. 2024
;390
(4
):326
-337
.30.
Hillmen
P
Cairns
DA
, Bloor
AJC
, et al. Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: report of the phase III UK NCRI FLAIR study
. Blood
. 2023
;142
(Suppl 1
):631
.31.
Shadman
M
, Munir
T
, Ma
S
, et al. Zanubrutinib and venetoclax for patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma with and without del(17p)/TP53 mutation: SEQUOIA Arm D results
. J Clin Oncol
. 2025
;43
(21
):2409
-2417
.32.
Niemann
CU
, Munir
T
, Moreno
C
, et al. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open- label, randomised, phase 3 trial
. Lancet Oncol
. 2023
;24
(12
):1423
-1433
.33.
Huber
H
, Tausch
E
, Schneider
C
, et al. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53mut
. Blood
. 2023
;142
(11
):961
-972
.34.
Davids
MS
, Lampson
BL
, Tyekucheva
S
, et al. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study
. Lancet Oncol
. 2021
;22
(10
):1391
-1402
.35.
Soumerai
JD
, Mato
AR
, Dogan
A
, et al. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
. Lancet Haematol
. 2021
;8
(12
):e879
-e890
.36.
Rogers
KA
, Huang
Y
, Ruppert
AS
, et al. Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naïve and relapsed or refractory chronic lymphocytic leukemia
. J Clin Oncol
. 2020
;38
(31
):3626
-3637
.37.
Woyach
JA
, Yin
J
, Brown
JR
et al. Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance)
. J Clin Oncol
. 2023
;41
(Suppl 16
):7500
.38.
Davids
MS
, Ryan
CE
, Lampson
BL
, et al. Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-naïve chronic lymphocytic leukemia population enriched for high-risk disease
. J Clin Oncol
. 2025
;43
(7
):788
-799
.39.
Rawstron
AC
, Howard
D
, McParland
L
et al. Compartment effect on the prognostic significance of MRD detection in CLL: impact of treatment type and duration of follow-up
. Blood
2016
;128
(22
):3226
.40.
Ghia
P
, Wierda
WG
, Barr
PM
et al. Relapse after first-line fixed duration ibrutinib + venetoclax: high response rates to ibrutinib retreatment and absence of BTK mutations in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with up to 5 years of follow-up in the phase 2 captivate study
. Blood
2023
;142
(Suppl 1
):633
.Copyright © 2025 by The American Society of Hematology
2025
You do not currently have access to this content.
